2024
LB862 Psychosocial burden of autoimmune blistering diseases (AIBD): A comprehensive survey study
Hoffman V, White M, Yale M, Strong R, Tomayko M. LB862 Psychosocial burden of autoimmune blistering diseases (AIBD): A comprehensive survey study. Journal Of Investigative Dermatology 2024, 144: s150. DOI: 10.1016/j.jid.2024.06.1242.Peer-Reviewed Original ResearchPsychosocial burden of autoimmune blistering diseases: A comprehensive survey study
White M, Hoffman V, Yale M, Strong R, Tomayko M. Psychosocial burden of autoimmune blistering diseases: A comprehensive survey study. Journal Of The European Academy Of Dermatology And Venereology 2024 PMID: 38837452, DOI: 10.1111/jdv.20156.Peer-Reviewed Original ResearchBody image disturbanceQuality of lifeDepressive symptomatologyImage disturbanceHigher levels of depressive symptomatologyLevels of body image disturbanceIncreased incidence of psychiatric disordersLevels of depressive symptomatologyIncidence of psychiatric disordersSelf-reported psychiatric historyBody image variablesBody image dissatisfactionMental health supportSurvey studyPsychiatric disordersPsychosocial impairmentPsychiatric historyPsychological constructsStudy of adultsEmail distribution listsImage dissatisfactionSelf-reportHealth supportPsychosocial consequencesBody image
2023
Polyinosinic: polycytidylic acid induced inflammation enhances while lipopolysaccharide diminishes alloimmunity to platelet transfusion in mice
Tran J, Muench M, Gaillard B, Darst O, Tomayko M, Jackman R. Polyinosinic: polycytidylic acid induced inflammation enhances while lipopolysaccharide diminishes alloimmunity to platelet transfusion in mice. Frontiers In Immunology 2023, 14: 1281130. PMID: 38146372, PMCID: PMC10749330, DOI: 10.3389/fimmu.2023.1281130.Peer-Reviewed Original ResearchConceptsB cell responsesPlatelet transfusionsMajor histocompatibility complexCell responsesPrior exposurePlatelet alloimmunizationMemory B cell responsesPlatelet transfusion recipientsSubsequent platelet transfusionsAllogeneic platelet transfusionsNegative bacterial infectionsPolyinosinic-polycytidylic acidGerminal center formationPrior inflammationAlloantibody responsesAlloimmune responsePlatelet refractorinessFuture transplantTransfusion recipientsMHC tetramersAdverse reactionsInflammatory environmentAntigen experiencePlatelet antigensTransfusionEnhanced alloresponse to platelet transfusion due to immune dysregulation following ablative chemotherapy in mice
Jackman R, Darst O, Gaillard B, Tran J, Tomayko M, Muench M. Enhanced alloresponse to platelet transfusion due to immune dysregulation following ablative chemotherapy in mice. Frontiers In Immunology 2023, 14: 1281123. PMID: 38090570, PMCID: PMC10711281, DOI: 10.3389/fimmu.2023.1281123.Peer-Reviewed Original ResearchConceptsAblative chemotherapyAlloantibody responsesPlatelet transfusionsB cellsPotent immunological effectsT cell responsesImpact of chemotherapyTransitional B cellsAllogeneic platelet transfusionsRisk of alloimmunizationNon-specific activationSubsequent transfusionsAllogeneic plateletsLymphocyte depletionBlood transfusionImmune dysregulationPlatelet recipientsSerum levelsPatient populationImmunological effectsImmunological environmentTransfusionRejection of transplantsChemotherapyHealthy peopleTargeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors. British Journal Of Dermatology 2023, 190: 138-138. PMID: 37947404, DOI: 10.1093/bjd/ljad342.Peer-Reviewed Original ResearchMicrofluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection
Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.Peer-Reviewed Original ResearchConceptsB cell depletion therapyAcute COVID infectionAnti-spike IgGHigh-risk patientsCoronavirus disease-19COVID-19 pathologyDepletion therapyVaccine protectionAntibody responseCOVID infectionHematologic malignanciesImmune protectionDisease-19Healthy donorsMultiple time pointsSerology assaysBlood samplesSoluble markersB cellsImmunization strategiesPatientsFunctional deficiencySerological analysisTime pointsClonotype diversityImmune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearanceHigh-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq
Liu Y, DiStasio M, Su G, Asashima H, Enninful A, Qin X, Deng Y, Nam J, Gao F, Bordignon P, Cassano M, Tomayko M, Xu M, Halene S, Craft J, Hafler D, Fan R. High-plex protein and whole transcriptome co-mapping at cellular resolution with spatial CITE-seq. Nature Biotechnology 2023, 41: 1405-1409. PMID: 36823353, PMCID: PMC10567548, DOI: 10.1038/s41587-023-01676-0.Peer-Reviewed Original Research
2021
COVID‐19 outcomes in patients with autoimmune blistering disease
Hwang E, Tomayko M. COVID‐19 outcomes in patients with autoimmune blistering disease. British Journal Of Dermatology 2021, 185: 1048-1050. PMID: 34107059, PMCID: PMC8239772, DOI: 10.1111/bjd.20571.Peer-Reviewed Original Research30 Rituximab
Gehlhausen J, Heffernan M, Tomayko M. 30 Rituximab. 2021, 330-338.e3. DOI: 10.1016/b978-0-323-61211-1.00030-9.ChaptersMucous membrane pemphigoidEpidermolysis bullosa acquisitaMechanism of actionCutaneous lupusHost diseaseBullous pemphigoidPemphigus vulgarisPemphigus foliaceusRituximabB cellsUS FoodDrug AdministrationDermatologic usesMonoclonal antibodiesPemphigoidTreatmentCD20AcquisitaLupusFoliaceusGraftDiseaseAdministrationAntibodiesPharmacology
2020
Rituximab
Gelhausen, J.R., Heffernan, M. P. and Tomayko, M.M. Chapter 30: Rituximab. In Comprehensive Dermatologic Drug Therapy, 4th Edition. Ed. S. E. Wolverton and J.J. Wu. 2020.Books
2019
A Niche for Plasma Cells: The Skin
Karaaslan S, Tomayko MM. A Niche for Plasma Cells: The Skin. Journal Of Investigative Dermatology 2019, 139: 2411-2414. PMID: 31753124, DOI: 10.1016/j.jid.2019.06.133.Peer-Reviewed Original ResearchB cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal For ImmunoTherapy Of Cancer 2019, 7: 153. PMID: 31200747, PMCID: PMC6567557, DOI: 10.1186/s40425-019-0613-1.Peer-Reviewed Original ResearchConceptsPD-1 inhibitorsB cell contentB-cell depletionAnti-tumor activityB cellsMuMT miceCell depletionAnti-PD-1 inhibitorsAnti-PD-1 responseB-cell depleting drugsTumor-infiltrating B cellsImpaired B-cell functionT cell-dependent tumor rejectionPD-1 inhibitionMC38 colon cancerB cell functionAnti-tumor effectsB-cell malignanciesMurine cancer modelsCell contentOverall survivalTumor rejectionCD20 antibodyAutoimmune disordersTumor shrinkageWhat B cell memories are made of
Tomayko MM, Allman D. What B cell memories are made of. Current Opinion In Immunology 2019, 57: 58-64. PMID: 30861463, DOI: 10.1016/j.coi.2019.01.003.Peer-Reviewed Original ResearchConceptsMemory B cellsB cell memoryB cellsPlasma cellsCell memoryAntigen-specific B cell receptorProtective serum antibodiesB cell receptorHumoral immunityIgG antibodiesSerum antibodiesSecondary exposureCell receptorUltimate outcomeAntigenAntibodiesMolecular eventsSame cellular pathwaysCellsCellular pathwaysIgMPathwayImmunityReceptors
2018
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal Of The American Academy Of Dermatology 2018, 80: 990-997. PMID: 30399387, PMCID: PMC6420863, DOI: 10.1016/j.jaad.2018.10.062.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsDrug EruptionsExanthemaFemaleHumansIpilimumabLichenoid EruptionsMaleMiddle AgedNivolumabRetrospective StudiesSkin NeoplasmsStevens-Johnson SyndromeWithholding TreatmentConceptsInflammatory eruptionsCheckpoint inhibitorsTherapeutic responseImmune checkpoint inhibitor therapySingle tertiary care centerSingle-institution retrospective analysisYale-New Haven HospitalCheckpoint inhibitor therapyTertiary care centerMinority of patientsInpatient dermatology serviceDegree of severityMost rashesInhibitor therapyRetrospective studyTopical treatmentEarly recognitionMedical recordsCare centerInflammatory reactionRetrospective analysisDermatology servicesImmunotherapyMean latencyGrade 2Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal Of The American Academy Of Dermatology 2018, 79: 1081-1088. PMID: 30025829, DOI: 10.1016/j.jaad.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenDrug EruptionsFemaleHumansLichenoid EruptionsMaleMiddle AgedNeoplasm ProteinsNeoplasmsNivolumabPemphigoid, BullousProgrammed Cell Death 1 ReceptorRetrospective StudiesSkin Diseases, VesiculobullousTertiary Care CentersTreatment OutcomeConceptsPD-L1 therapyAnti-PD-1/PD-L1 therapyBullous disordersBullous eruptionPD-1/PD-L1 therapyCell death ligand-1 therapyAnti-programmed cell death 1Cancer therapyDeath ligand 1 therapySingle tertiary care centerLinear IgA bullous dermatosisYale-New Haven HospitalDistinct therapeutic challengesInterruption of immunotherapyPositive tumor responseSteroid-sparing agentTertiary care centerIgA bullous dermatosisCell death 1New Haven HospitalStable diseaseSystemic corticosteroidsSystemic steroidsMaintenance therapyL1 therapy
2017
B Cell Biology
Sadanand S, Tomayko M. B Cell Biology. 2017, 97-119. DOI: 10.1007/978-3-319-29785-9_7.ChaptersB cell biologyCell biologyB cellsImmune responseEffector functionsB cell-T cell interactionsCell-T cell interactionsB cell developmentCurrent therapeutic mechanismsRegulatory B cellsB-cell depletionB cell responsesAdaptive immune responsesMemory B cellsGerminal center responseEstablishment of toleranceCell developmentCentral playerProtective immunityCell depletionDurable immunityAntigenic targetsAntibody isotypesPlasma cellsTherapeutic mechanism
2016
Development of bullous pemphigoid during nivolumab therapy
Damsky W, Kole L, Tomayko MM. Development of bullous pemphigoid during nivolumab therapy. JAAD Case Reports 2016, 2: 442-444. PMID: 27981213, PMCID: PMC5144742, DOI: 10.1016/j.jdcr.2016.05.009.Peer-Reviewed Original Research
2015
Nodular plaque in a cardiac transplant patient
Waldman A, Ezaldein H, Tomayko M, Galan A. Nodular plaque in a cardiac transplant patient. Journal Of The American Academy Of Dermatology 2015, 72: e111-e112. DOI: 10.1016/j.jaad.2014.12.037.Peer-Reviewed Original Research
2014
Pemphigus vulgaris presenting as gingival hypertrophy in a child
Haberland C, Johnson M, Tomayko M. Pemphigus vulgaris presenting as gingival hypertrophy in a child. Oral Surgery Oral Medicine Oral Pathology And Oral Radiology 2014, 118: e191. DOI: 10.1016/j.oooo.2014.05.088.Peer-Reviewed Original Research